(UroToday.com) The principal objectives of TRACERx Renal consortium are to define drivers and intra-tumor heterogeneity in renal cell carcinoma (RCC) and determine the relationship between heterogeneity and disease stage, clinical outcome, and treatment response. Additionally, other objectives include the identification of drivers of metastatic progression and drug response or resistance. Furthermore, it aims to establish the utility of cell-free tumor DNA in patients’ blood and urine as a predictive biomarker in RCC. TRACERx Renal consortium also aims to assess the impact of the genomic landscape upon anti-tumor T cell responses, especially in the context of immunotherapy.